Skip to main content
SpringerLink
Log in

Einfluss von Dapagliflozin auf die endogene Glukoseproduktion bei Typ-2-Diabetes

Effect of dapagliflozin on endogenous glucose production in type 2 diabetes

  • Journal Club
  • Published:
Die Diabetologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. DeFronzo RA, Norton L, Abdul-Ghani M (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13:11–26

    Article  CAS  Google Scholar 

  2. Merovci A, Solis-Herrera C, Daniele G et al (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124:509–514

    Article  CAS  Google Scholar 

  3. Ferrannini E, Muscelli E, Frascerra S et al (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499–508

    Article  CAS  Google Scholar 

  4. Abdul-Ghani MA, DeFronzo RA, Norton L (2013) Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50 % of filtered glucose load in humans. Diabetes 62:3324–3328

    Article  CAS  Google Scholar 

  5. Alatrach M, Laichuthai N, Martinez R et al (2020) Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors. Diabetes 69:681–688

    Article  CAS  Google Scholar 

  6. Martinez R, Al-Jobori H, Ali AM et al (2018) Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy. Diabetes 67:1182–1189

    Article  CAS  Google Scholar 

  7. Qin Y, Adams J, Solis-Herrera C, Triplitt C, DeFronzo R, Cersosimo E (2020) Clinical parameters, fuel oxidation and glucose kinetics in type 2 diabetes patients treated with dapagliflozin plus saxagliptin. Diabetes Care 43:2519–2527

    Article  CAS  Google Scholar 

  8. Daniele G, Solis-Herrera C, Dardano A et al (2020) Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. Diabetologia 63:2423–2433

    Article  CAS  Google Scholar 

  9. Giaccari A (2022) SGLT2i increase endogenous glucose production: that’s good news! Diabetes Care 45:1301–1302

    Article  CAS  Google Scholar 

  10. Pradhan R, Yin H, Yu O, Azoulay L (2022) Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes. Diabetes Care 45:819–829

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetesschwerpunktpraxis, Rodensteinstr. 32, Berlin, Deutschland

    Michael Jecht

Authors
  1. Michael Jecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Jecht.

Ethics declarations

Interessenkonflikt

M. Jecht hat durch die Firma AstraZeneca Vortragshonorare erhalten.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jecht, M. Einfluss von Dapagliflozin auf die endogene Glukoseproduktion bei Typ-2-Diabetes. Diabetologie 18, 754–755 (2022). https://doi.org/10.1007/s11428-022-00942-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-022-00942-0

Search

Navigation